Special Issue "Cancer Stem Cells in Major Smoking Related Cancers"
Deadline for manuscript submissions: 15 June 2024 | Viewed by 116
Interests: early cancer diagnosis; cancer risk assessment; molecular biologic basis of head and neck; lung and genitourinary cancer; cancer immunotherapy
Interests: Cancer signaling; Cancer immunology; Cancer metabolism; Targeted therapy; Repurposed drugs
Special Issues, Collections and Topics in MDPI journals
Special Issue in International Journal of Molecular Sciences: Fifty Years of Targeted Therapy in Cancer: Past, Present and Future
Special Issue in International Journal of Molecular Sciences: Role of Different Metabolic Pathways on Development and Progression of Cancer
Therapeutic resistance remains a significant hurdle in treating patients with different types of cancer, including lung cancer, bladder cancer, and head and neck cancer. These three cancer types are closely associated with active and/or passive smoking. The chemicals present in tobacco smoke can cause DNA damage that enhances genetic and epigenetic alterations at the cellular level, eventually leading to the development of neoplastic changes. The risk of other cancer types, such as esophageal cancer, pancreatic cancers, kidney cancer, and cervical cancer, is also known to be increased due to smoking exposure. Numerous environmental exposures (such as smoking) have been reported to be associated with inducing different molecular alterations, initiating and promoting cancer stem cells (CSCs), and ultimately contributing to therapeutic resistance. It is important to note that the relationship between smoking and cancer stem cells is complex and multifactorial, and more research is needed to fully understand the underlying mechanisms. This Special Issue entitled “Cancer Stem Cells in Major Smoking Related Cancers” aims to highlight recent advancements in CSC research associated with therapeutic resistance that could improve cancer management and treatment.
Dr. Mohammad O. Hoque
Dr. Pritam Sadhukhan
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cancer stem cells
- cancer recurrence
- therapeutic resistance
- tumor microenvironment
- cancer signaling pathways
- targeted therapy
- head and neck cancer
- lung cancer
- bladder cancer
- esophageal cancer
- pancreatic cancers
- kidney cancer
- cervical cancer